Combining the amplification refractory mutation system and high-resolution melting analysis for KRAS mutation detection in clinical samples.

ABSTRACT: The success of personalized medicine depends on the discovery of biomarkers that allow oncologists to identify patients that will benefit from a particular targeted drug. Molecular tests are mostly performed using tumor samples, which may not be representative of the tumor's temporal and spatial heterogeneity. Liquid biopsies, and particularly the analysis of circulating tumor DNA, are emerging as an interesting means for diagnosis, prognosis, and predictive biomarker discovery. In this study, the amplification refractory mutation system (ARMS) coupled with high-resolution melting analysis (HRMA) was developed for detecting two of the most relevant KRAS mutations in codon 12. After optimization with commercial cancer cell lines, KRAS mutation screening was validated in tumor and plasma sam

SUBMITTER: Oliveira BB 

PROVIDER: S-EPMC10185647 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature